# A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy

> **NCT07673809** · PHASE1,PHASE2 · RECRUITING · sponsor: **AO GENERIUM** · enrollment: 32 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **GENETIC:** GNR-097
- **GENETIC:** Placebo followed by GNR-097

## Key facts

- **NCT ID:** NCT07673809
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2029-08-02
- **Final completion:** 2029-08-02
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673809, "A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07673809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*